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AbstrAct
Larynx cancer organ preservation treatments with chemo and radiotherapy have 
substantially improved laryngoesophageal dysfunction-free survival. However, both 
of them lead to a high incidence of acute and chronic toxicities and a significant 
number of patients relapse. To date, there is no evidence available to establish the 
group of patients that may benefit from preservation approaches and clinical criteria 
such as primary tumor extension or pretreatment tracheotomy are not validated. 
MAP17 is a small non-glycosylated membrane protein overexpressed in carcinomas. 
The tumoral behavior induced by MAP17 is associated with reactive oxygen species 
production in which SGLT1 seems involved. In this study we found that the levels 
of MAP17 were related to clinical findings and survival in a cohort of 58 patients 
with larynx cancer. MAP17 expression is associated with overall survival (p<0.001) 
and laryngoesophageal dysfunction-free survival (p=0.002). Locoregional control 
in patients with high MAP17 showed better outcomes than those with low MAP17 
(p=0.016). Besides, a positive correlation was observed between MAP17 expression 
and SGLT (p=0.022) and the combination of high levels of MAP17/SGLT also led to 
an increased overall survival (p=0,028). These findings suggest that MAP17, alone or 
in combination with SGLT1, may become a novel predictive biomarker for laryngeal 
carcinoma.
INtrODUctION
Squamous cell carcinoma of the head and neck 
represents 4% of all cancers diagnosed worldwide, with 
>500.000 new cases recorded in 2008. Of them, 151.000 
cases (130.000 men and 21.000 women) were laryngeal 
cancer with an estimated age-standardized world mortality 
rate of 2.3/100.000 habitants. In fact, 82.000 deaths were 
estimated in 2008 due to this cause [1].
Alcohol and tobacco abuse are common etiologic 
factors [2] but exposure to hard-alloys dust, chlorinated 
solvents [3] and familiar genetic patterns [4] have been 
also implicated. The role of Human Papilomavirus (HPV) 
is well established for squamous cell carcinoma of the 
oropharynx but it remains unclear for laryngeal cancer 
[5]. Besides, these patients are at risk of developing 
second primary tumors due to chronic aerodigestive tract 
carcinogen exposure: 14% in 5 years, 26% in 10 years and 
37% in 15 years [6].
The main prognostic factor for overall survival (OS) 
is tumor staging, where node invasion is more relevant 
than tumor extension [7]. Other OS prognostic factors are 
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patient’s comorbidity, performance status-ECOG (PS) [8], 
persistent toxic consumption habits [9], second primary 
tumor appearance [10] and primary tumor localization. In 
particular, glottic tumors reach 81% OS rates meanwhile 
supraglottic tumors drop to 70%, probably due to early 
detection [11]. Moreover, PS [8,12], node invasion [12,13] 
and localization [8] are prognostic factors for disease-
free survival in conjunction with pathologic stage (pT) 
[13], surgical resection margins [12] and pretreatment 
tracheotomy [14]. 
Until the 1980s, total laryngectomy surgery was 
the standard treatment with subsequent loss of speech 
and airway patency [15]. Consequently, treatment aims 
changed in order to improve patient’s quality of life 
through larynx sparing approaches. Organ preservation 
treatments for laryngeal cancer patients depend on 
whether the tumor is presented in early stages (I and II) or 
advanced locoregional disease (stage III/IV). In general, 
early stages are treated with either primary surgery or 
definitive radiotherapy (RT). Five-year OS in patients with 
stage I or stage II disease is typically 70 to 90%. Surgery 
and RT seem to have similar effectiveness in this setting 
although they have not been compared in a randomized 
trial [16,17]. Advanced disease requires multimodal 
approach, usually a combination of chemotherapy (CT) 
or biotherapy (B) with cetuximab plus RT. Although 
functional organ sparing approaches permit larynx 
preservation they do not provide a survival advantage 
over total laryngectomy [18]. Currently, three sparing 
approaches are accepted: RT, bio/chemo/radiotherapy (B/
CTRT) and induction CT (ICT) followed by B/CTRT.
Regarding B/CTRT, cisplatin showed higher 
preservation rates as compared with induction CT followed 
by RT or RT alone (88% vs. 75% and 70%, respectively) 
with similar two and five year survival [19]. Later, a 10-
year follow up publication confirmed that the arms that 
included CT improved laryngectomy-free survival [20]. 
Besides, a subsequent meta-analysis for locally advanced 
larynx cancer found that adding CT concomitant with RT 
led to a benefit of 6.5% absolute improvement in 5-year 
OS [21]. As for bio-radiotherapy, RT plus cetuximab 
showed better locoregional control rates than RT alone for 
advanced head and neck cancers [22]. A subset analysis of 
this study with hypopharyngeal and laryngeal carcinoma 
patients showed a hazard ratio (HR) 0.62 preservation in 
the cetuximab arm but this was not statistically significant 
[23].
With respect to ICT, the Veterans study 
demonstrated 64% preservation larynx rate without 
worsening survival in the induction followed by RT 
arm compared with surgery plus RT [24]. Afterwards, 
induction treatments were developed and the docetaxel, 
cisplatin and 5-Fluorouracil (DCF) schedule became the 
standard treatment, preserving the larynx 15% more than 
cisplatin and 5-Fluorouracil [25]. Furthermore, cetuximab 
has been studied as a concurrent treatment with RT instead 
of cisplatin after DCF induction chemotherapy, showing 
similar larynx preservation results in a phase II trial [26]. 
However, these strategies of treatment entail up to 
a 43% rate of late toxicities [27] and have not shown to 
prolong OS more than radical treatments. Interestingly, 
5-year OS has decreased from 67.4% in 1985 to 59.6% 
in 2006 despite the development of new therapies for 
larynx cancer (Source: Surveillance, Epidemiology 
and End Results Program. Accessed: http://seer.cancer.
gov/). One of the reasons that could justify this issue is 
that preservation approaches were not broadly used until 
the time of database collection. These two facts lead to 
the need for developing predictive biomarkers in order 
to select the patients that may benefit from preservation 
techniques and are not going to suffer unnecessary 
toxicities.
MAP17 is a small 17 Kda membrane protein present 
in a high proportion of tumors, not only in carcinoma. It 
has been found present in adenoma and benign tumors, 
and is highly expressed in metastatic carcinoma. 
Furthermore, its expression correlates with staging and 
malignant status of the tumor [28]. The expression is 
mainly driven at a transcriptional level either by promoter 
activation or demethylation [29, 30]. Expression of 
MAP17 in primary cells triggers senescence through p38, 
but in tumoral cells enhances the malignant capabilities of 
these cells, increasing proliferation, migration, resistance 
to apoptosis, etc [31,32]. MAP17 expression increases 
the levels of reactive oxygen species (ROS) in cells 
which may account for some of the increased tumoral 
properties [33]. In turn, a further increase of ROS might 
switch the balance towards apoptosis. Thus, MAP17 may 
increase the efficacy of therapies increasing ROS and 
therefore constitute a biomarker for better prognosis of 
these tumors. In cervix tumors treated with cisplatin and 
radiotherapy, high levels of MAP17 mark good survival 
of the patients [30]. Therefore, MAP17 is not only a 
marker for stage and malignant status but also may be a 
marker of prognosis and response to therapies involving 
oxidative stress. In this manuscript we have explored the 
relevance of the presence of MAP17 in larynx tumors 
where primary response is mainly achieved by treatments 
with radiotherapy and cisplatin or other radiosensitizers.
rEsULts
clinical cohort description
At the time of the analysis, 21 (32%) deaths and 31 
(48%) recurrences had occurred with a median follow-up 
of 29 months. The most common cause of LDS failure was 
local recurrence, which required salvage laryngectomy 
in 16 (52%) of cases. Mean OS was 58.2 months (48.7-
67.7, CI 95%) and mean LDS 44.6 (35.2-54.1, CI 95%). 
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Lymph node metastases were significantly associated 
with decreased OS (N0: 63.1 m, N1: 38.6 and N2 22.2 
m, p=0.019) while tumor local extension impacted 
LDS negatively (T4 extension 7.3 m vs. 47.1m non T4 
extension, p=0.003). Besides, patients who required 
pretreatment tracheotomy had significantly worse LDS 
(54.3 vs. 18.9 months, p=0.001). The two-year cumulative 
proportion of patients with larynx preservation and OS 
were 57% and 76% respectively. Besides, locoregional 
control rate at two years was 60%. Therefore, our cohort 
behaves similarly to others reported in the literature 
[19,24].
MAP17 expression in larynx tumor samples
Out of 65 samples, only 58 were analyzed for 
MAP17 expression, either due to technical problems or 
because they did not contain any tumor cellularity. Out 
of the 58 samples, 46 (79%) were positives for MAP17 
expression (Figure 1A,B and 1C) and there was a trend 
showing higher levels of MAP17 in advanced grades of the 
tumor (Figure 1D), although in this case, probably due to 
the low number of cases, it was not statistically significant. 
Surrounding normal tissue did not express MAP17 or 
expressed very low levels. We also analyzed other markers 
for proliferation such as KI67 or the activated form of 
ERK (phosphorylated ERK, ERK-p), or apoptosis such 
as mutant p53 or activated AKT (phosphorylated AKT, 
AKT-p). Our cohort showed a percentage of samples 
positive for KI67, mutant p53, ERK-p or AKT-p, but 
these groups did not show correlation with MAP17 levels 
(Figure 2). However, KI67 positivity showed statistically 
significant correlation with OS (Table 2). No correlation 
of MAP17 was observed with clinical parameters such as 
tumor localization, smoking habit, alcohol consumption, 
tumoral stage, pre-treatment tracheotomy and development 
of acute toxicities during chemoradiotherapy. 
Figure 1: MAP17 overexpression in larynx tumors. A) Representative images of MAP17 immunostaining are shown for different 
larynx tumors. B) High magnification of M17 positive and negative tumors. The picture shows a magnification of the inset of figure A. C) A 
graph is shown representing the percentage of laryngeal tumors with dichotomous MAP17 levels. The score for positive tumors were >62. 
D) The distribution of the MAP17 expression levels among different grades of larynx tumors is shown. The MAP17 levels (score) refers 
to maximum levels (0–2) scored by the percentage of cells (0–100). The normalized levels were obtained by multiplying the percentage 
of cells by the level of intensity observed. Anova test was performed to establish the statistical association between MAP17 protein levels 
and the grade of the tumor (p<0,05).
Oncotarget12628www.impactjournals.com/oncotarget
table1: Population characteristics and treatment.
characteristics               No.                 %
Mean age                                                     62 years                                                 
Male 61 94
Squamous cell carcinoma 65 100
Cigarette smoking
     Current smokers
     Former smokers
     Never smokers
44
19
2
68
29
3
Smokers of ≥ 10 pack-years 60 92
Regular alcohol intake 46 71
PS 0-1 62 95
Pretreatment tracheotomy 21 32
Localization
    Supraglottic
    Glottic
    Subglottic
39
24
2
60
37
3
TNM Staging      
     II
     III
     IV
6
49
10
9
75.5
15.5
Treatment approach
     Surgery
     Radiotherapy
     B/CTRT
     ICT-B/CTRT
1
9
49
6
2
14
75
9
PS: Performance status-ECOG; B/CTRT: bio/chemoradiotherapy; 
ICT-B/CTRT: induction chemotherapy followed by bio/
chemoradiotherapy.
table 2:  Laryngoesophageal dysfunction-free survival (LDs) and overall survival (Os) multivariate analysis of 
laryngeal cancer patients treated with preservation approaches.
LDS OS
Factors HR p-value CI HR p-value CI
Ki67
P53
SGLT
MAP17 
PS=2
Pret. Tracheo.
RT
Bio/CTRT
ICT-bio/CTRT
Stage II
Stage III
1.001
0.982
1.007
32.66
13.99
1.476
0.161
0.046
0.047
0.224
0.636
0.938
0.209
0.238
0.001
0.019
0.431
0.258
0.080
0.101
0.202
0.500
0.976-1.027
0.956-1.010
0.995-1.019
4.352-245.1
1.534-127.7
0.560-3.890
0.007-3.804
0.001-1.452
0.001-1.805
0.023-2.228
0.171-2.367
1.053
1.016
0.993
21.73
4.162
1.849
0.042
0.109
0.014
0.402
0.048
0.050
0.477
0.497
0.010
0.446
0.505
0.161
0.447
0.169
0.703
0.016
1.000-1.108
0.972-1.062
0.972-1.014
2.071-228.1
0.106-162.8
0.304-11.26
0.000-3.549
0.000-33.00
0.000-6.054
0.004-43.73
0.004-0.569
Pret. Tracheo.: pretreatment tracheotomy required. PS: ECOG-performance status. B/CTRT: bio/chemoradiotherapy; 
ICT-B/CTRT: induction chemotherapy followed by bio/chemoradiotherapy.
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sGLt1 overexpression in human larynx tumors 
correlates with MAP17 levels
Previous results indicate that MAP17-dependent 
tumorigenic properties depend on the indirect activation 
of ROS by SGLT1 transport and that there is a correlation 
between the expressions of both markers in cervix tumors 
[30]. Therefore, we measured SGLT1 expression levels 
in the same cohort of larynx tumor samples. We found 
that some tumors showed positive SLGT1 staining, with 
approximately 40% tumors being positive for SLGT1 
(Figure 3 A,B,C and D). However, only a few samples 
showed very high staining levels. The distribution of 
the SGLT1-positive tumors among the different larynx 
tumors showed a clear correlation with MAP17 expression 
(Figure 3E,F and G). Pearson indicator expressed a 
positive significant correlation between MAP17 and SGLT 
(P=0.3, p=0.022).
MAP17 as predictive biomarker for laryngeal 
cancer
The high MAP17 group correlated in this study with 
better OS, LDS and locoregional control. When MAP17 
was measured as a constant variable, multivariate Cox 
model demonstrated that higher rates of MAP17 levels 
correlated with improved OS (HR: 0.98, p= 0.001). 
Nevertheless, this could not be confirmed for LDS (HR 
0.99, p=0.8), probably due to the limited number of cases. 
In order to distinguish a cutoff point for MAP17 
levels a ROC curve was performed and punctuation of 62 
score chosen. When measured as a dichotomous variable, 
MAP17 high rates (>62) were related with increased 
OS, LDS, and locoregional control. A difference of 35.3 
months was observed between high MAP17 levels (67 
months) and low MAP17 levels (31.7 m) in Kaplan-
Meier model (IC 95%; p<0.001) and the HR estimator 
for high MAP17 was 0.78, p=0.002 in the multivariate 
analysis (Figure 4). Regarding LDS, high MAP17 showed 
a survival benefit of 13.1m (47.6 m vs. 34.5 m, p=0.002) 
with a HR: 0.14, p=0.003 in multivariate analysis. The 
effect of MAP17 high levels on the improved survival was 
significant after controlling for other variables: P53, Ki67, 
SGLT, PS, TNM, pretreatment tracheotomy and treatment 
received and shown in table 2. Regarding locoregional 
control, patients with high MAP17 showed to have better 
outcomes than low MAP17 (53.9 m vs 44.5 m, p=0.016) 
and the results were confirmed in the multivariate model 
(p=0.045).
Figure 2: p53, Ki67, p-ErK or p-AKt do not show correlation with MAP17 expression in larynx tumors. A) Representative 
images of p53, Ki67, p-ERK or p-AKT immunostainings are shown for larynx tumors. B) Graphs showing lack of correlation between these 
proliferative or antiapoptotic markers and MAP17 expression.
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However, although MAP17 correlated with SGLT 
in the Pearson model (Figure 3E), SGLT alone did not 
show statistically significant correlation with OS or LDS 
(results not shown). Moreover, the associated high levels 
of MAP17 and SGLT did show improved OS than MAP17 
alone (72.4 m vs 42m, p=0,028) (Figure 4D).
These data confirm that MAP17 alone, or preferably 
combined with SGLT1, is a good prognostic marker for 
survival in patients with larynx cancer treated with B/
CTRT.
tumor cells overexpressing MAP17 are more 
sensitive to radiation
To explore whether MAP17 may be causal in this 
response, we expressed MAP17 cDNA in Hela cells and 
subjected these cells and their parental expressing only 
empty vector, to different doses of radiotherapy. Our 
data showed that Hela cells expressing MAP17 (Figure 
5A) were more sensitive to radiation than parental cells 
without MAP17 (Figure 5B), therefore confirming the 
causal role of MAP17 in the sensitivity to radiation.
Finally, to test our initial hypothesis of the relevance 
of ROS in the MAP17-enhanced radiosensitivity of Hela 
cells, we treated the cells with antioxidants GSH and 
NAC, and subjected these cells to different radiation doses 
(Figure 5C and D). We observed that both antioxidant 
treatments reduced the sensitivity of MAP17-expressing 
Hela cells to a range similar to parental cells, which 
remains mostly unaltered (Figure 5C and D).
These data confirm the relevance of the oxidative 
status of the tumors in the response to radiation.
Figure 3: sGLt1 overexpression in larynx tumors. A) Representative images are shown of SGLT1 immunostaining of different 
larynx tumors. B) High magnification of SGLT1 positive and C) negative tumors. D) Graph representing the percentage of larynx tumors 
positive or negative for SGLT1 expression. E) Graph representing the correlation between MAP17 and SGLT1 expression in each tumor. 
The statistical analysis was performed by Pearson correlation (p=0,0022). F) Samples from one patient showing clear correlation between 
the expression of MAP17 and SGLT1. G) High magnification of samples from one patient showing clear correlation between the expression 
of MAP17 and SGLT1.
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DIscUssION
MAP17 is a small 17 kDa non-glycosylated 
membrane protein overexpressed in human carcinomas 
[29]. Tumor cells with MAP17 overexpression show 
enhanced proliferative capabilities [31,32]. MAP17 
expression is associated with an SGLT-dependent ROS 
increase that acts as a second messenger enhancing 
tumorigenesis. While a mild increase in ROS has been 
shown to activate signaling cascades that upregulate 
tumorigenic processes, further ROS increases lead to a 
potentially toxic cellular environment and programmed 
cell death [33]. The hypothesis is that tumors expressing 
high levels of ROS producing MAP17 and SGLT1 proteins 
can benefit from therapies such as cisplatin or radiotherapy 
that increase oxidative stress and could sensitize them 
to cell death. In this setting, our analysis in laryngeal 
cancer showed a significant relationship between high 
MAP17 protein expression and increased OS, suggesting 
that MAP17 expression is an independent biomarker for 
survival. In fact, high MAP17 levels demonstrated better 
OS than low levels (67 months vs. 31.7 months, IC 95%; 
p<0.001). Our work also shows that patients with high 
MAP17 showed better locoregional control and LDS. 
Furthermore, the associated high levels of MAP17 and 
SGLT showed improved OS, better than MAP17 alone. 
These results are consistent with others presented in 
cervical cancer in which high levels of MAP17, better in 
Figure 4: MAP17 alone or in combination with sGLt1 are good independent markers for patient survival. A) 
Correlation of MAP17expression measured as a dichotomous variable, MAP17 high rates (>62) with overall survival. B) Correlation of 
MAP17expression measured as a dichotomous variable, MAP17 high rates (>62) with laryngoesophageal dysfunction-free survival. C) A 
Kaplan-Meier curve is shown indicating that MAP17 could be a good prognostic marker for overall survival in laryngeal tumor patients 
treated with radiotherapy plus bio/chemotherapy. D) A Kaplan-Meier curve shown indicates that combined high levels of MAP17 and 
SGLT1 levels are a good prognostic marker for survival in cervical tumor patients treated with radiotherapy plus adjuvant chemotherapy.
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combination with high SGLT1, correlated with improved 
patient survival after treatment [30]. Furthermore, proof 
of principle experiments in vitro demonstrated that 
antioxidant treatments reduced the sensitivity of MAP17-
expressing Hela cells to a range similar to parental cells, 
confirming the relevance of the oxidative status of the 
tumors in the response to Radiation. 
Our data confirm that MAP17 alone, and better in 
combination with SGLT1, is a good prognostic marker 
for survival in patients with larynx cancer treated with 
radiotherapy plus chemotherapy. Therefore, MAP17 could 
predict which patients may have better survival outcomes 
and would benefit from preservation approaches. Further 
prospective and controlled studies are needed in order 
to confirm our results and validate MAP17 as a novel 
biomarker of clinical use in larynx cancer.
MEtHODs
Patients characteristics and treatment
We evaluated 65 patients with larynx cancer and 
their treatment and evolution from August 2005 to 
February 2014. All patients expressed informed consent 
and the project was approved by the local ethical 
committee at HUVR. Patients received specific treatment 
in our institution while tumor samples were obtained from 
Figure 5: MAP17 overexpression in Hela cells induces sensitivity to radiotherapy. A) Hela cancer cells expressing ectopic 
MAP17 cDNA were selected and analyzed for MAP17 mRNA expression by quantitative RT-PCR. B) Hela cells expressing ectopically 
MAP17 cDNA (Hela-Map17) and parental cells expressing only empty vector (Hela) were seeded at equal concentration and subjected to 
different radiation doses as indicated, in triplicate samples. 48 hrs after treatment the percentage of survival cells was measured in each case 
and plotted in the graph. The experiment was performed three independent times in triplicate. C and D) Hela cells expressing ectopically 
MAP17 cDNA (Hela-Map17) and parental cells expressing only empty vector (Hela) were seeded at equal concentration and subjected to 
pretreatment with 10 mM GSH (C) or 10 mM NAC (D) during 18 hrs, then treated with different radiation doses as indicated, in triplicate 
samples. 48 hrs after treatment the percentage of survival cells was measured in each case and plotted in the graph. 
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four different national hospitals where the diagnosis was 
made. Eligibility criteria for preservation approaches 
in this study include patients with stage II-IV laryngeal 
tumors that had no contraindication for chemotherapy and/
or radiotherapy, significant cartilage destruction, or more 
than 2 cm of tumor infiltration in the base of the tongue. 
TNM Staging System for the Larynx (7th ed., 2010) 
was used for tumor classification. Patients were mainly 
male (94%) with squamous carcinoma and good general 
condition (PS 0-1: 95%). Tumors were more frequently 
localized in the supraglottic (60%) and 75.5% were stage 
III. Interestingly, 32% of patients required pretreatment 
tracheotomy. Most of the patients were candidates for 
organ preservation with B/CTRT (75%), RT (14%), or 
ICT-B/CTRT (9%). Preferred treatment concurrent to 
radiotherapy was cisplatin 100 mg per square meter 
on days 1, 22, and 43 of radiotherapy (74%) followed 
by weekly cisplatin 40 mg per square meter (11%) and 
monoclonal antibody cetuximab (11%). Carboplatin was 
chosen for 4% of patients. Population characteristics and 
treatments are detailed in Table1.
tissue acquirement and preparation.
Formalin-fixed, paraffin-embedded tissue sections 
from 65 laryngeal carcinomas were selected with the 
collaboration of the Andalusian Health Care Biological 
Resource Centre. Histological characterization of all 
samples was done by Hematoxylin and Eosin staining, 
followed by immunohistochemistry (IHQ) analysis of 
tissue microarrays (TMA).
Immunohistochemistry
Three-micrometer slices were sectioned from the 
TMA block and applied to coated, immunochemistry 
slides (DAKO, Glostrup, Denmark). The slides were 
baked overnight in a 56°C oven, deparaffinized in xylene 
for 20 min, rehydrated through a graded ethanol series and 
washed with PBS. A heat-induced epitope retrieval step 
was performed by heating a slide in a solution of sodium 
citrate buffer pH 6.5 for 2 min in a conventional pressure 
cooker. After heating, the slides were incubated with 
proteinase K for 10 min and rinsed in cool running water 
for 5 min. Endogenous peroxide activity was quenched 
with 1.5% hydrogen peroxide (DAKO) in methanol for 
10 minutes, and incubation with the primary antibodies 
anti-MAP17 (1:4) [29-33] and anti-SGLT1 (Abcam 
#14685) was performed for 40 min. After incubation, 
immunodetection was performed with the EnVision 
(DAKO, Glostrup, Denmark) visualization system using 
diaminobenzidinechromogen as the substrate, according 
to the manufacturer’s instructions. Immunostaining was 
performed in a TechMate 500 automatic immunostaining 
device (DAKO) and measured through a double-
blind visual assessment using microscopic observation 
according to the anatomopathological experience 
of pathologists. Sample scoring was performed by 
semiquantitative microscopic analysis, considering the 
number of stained cells and signal intensity. Both MAP17 
and SGLT stainings were performed. In both cases we 
used the score obtained by the multiplication of the 
intensity levels (1, 2 or 3) by the percentage of positive 
cells. For MAP17, the threshold used is the score of 62, 
obtained by ROC curve as the most relevant to establish as 
dichotomous variable. For SGLT1, there was no staining 
at all in non tumoral surrounding tissue, and the positivity 
was considered when positive cells were observed in the 
tumor. 
cell culture
Hela malignant cervical tumor cells were obtained 
from the European Collection of Cell Cultures (ECACC) 
human cell line repository and maintained in Dulbeccós 
modified Eaglés medium (Sigma) containing 10% fetal 
bovine serum (Sigma), penicillin, streptomycin and 
fungizone. MAP17 full-length cDNA was cloned into 
pBabepuro and mass culture generated by stable gene 
transfer in Hela cells. After selection with 2 µg/ML 
puromycin, mass cultures were used for the study. As a 
control, Hela cells were transfected with pBabepuro alone 
and selected. 
radiation treatment of in vitro culture
Cells were irradiated using Costar 24 well cell 
culture plates (Corning Incorporated, NY USA). To 
simulate actual radiobiological experimental conditions, 
each well was filled with culture medium. The plate 
dimensions were 12.5 x 8.5 cm. The inner diameter of the 
well was 16 mm and the distance between the centers of 
two neighboring wells was 20 mm. Plates were positioned 
inside a water-equivalent device, specifically designed to 
fit the plate. This device measures 16 x 16 x 2 cm, and 
is placed inside the IBA BodyPhantom (IBA Dosimetry 
GbmH, Schwarzenbruck, Germany) at a depth of 6 cm. 
Simulation was performed using a Toshiba Aquilion CT 
scanner (Toshiba Corporation, Japan). CT images were 
exported to the treatment planning system Philips Pinnacle 
V9.2 (Philips Radiation Oncology Systems, Madison, 
WI). Five plans were designed to deliver uniform doses 
of 0.1 Gray (Gy), 0.3 Gy, 1 Gy, 3 Gy and 10 Gy using 
static beams of 24 x18 cm. To verify the dose within 
every well, we delineated 24 regions of interest (ROI) that 
had a diameter of 16 mm. The ROI was estimated at the 
bottom of the wells and 5mm upwards. The dose delivered 
to the cells was verified with the IBA Compass system 
(IBA Dosimetry GbmH, Schwarzenbruck, Germany). 
Differences between the prescribed dose and the dose 
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received were within 3%. The irradiation was delivered 
using 6 megaelectronvolts (MV) photon beams from an 
Elekta Synergy Linac (Elekta Oncology System, Ltd, 
Crawley, UK) with a dose rate of 500 mu/min.
Statistical analysis and definitions
Kaplan-Meier method was used for survival 
analysis, using Cox Proportional Hazards model to adjust 
for the explanatory variables, obtain the p-values and 
estimate the HR. Multivariate logistic regression was 
used to obtain odds ratio (OR) and confidence intervals 
(CI 95%). Pearson’s correlation measured dependence 
between quantitative variables. A receiver operating 
characteristic (ROC) curve was performed to assess 
MAP17 cutoff point (three year overall survival), which 
we checked using the optimal Youden index-based 
point. In addition, a log-rank test compared the survival 
distributions between the high MAP17 levels and the low 
levels. Statistical calculations were performed using SPSS 
15.0 software.
OS has been defined as the length of time from the 
date of diagnosis until date of the last medical record. 
Adopting Lefebvre Larynx Preservation Consensus Panel 
(2009) for laryngoesophageal dysfunction-free survival 
(LDS), we considered endpoint events: death, local 
relapse, total or partial laryngectomy, tracheotomy at two 
or more years, or the presence of a feeding tube at two 
or more years [34]. Locoregional control was considered 
from the date of the diagnosis until local progression 
or last medical record, after excluding patients who 
developed distant metastases or died due to other causes 
not related to the larynx tumor.
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